Hemostasis Analyzers Market Size, Trends and Growth Analysis by 2027

The hemostasis analyzers market is anticipated to grow significantly, with projections indicating it will reach US$ 6,490.24 million by 2028, up from US$ 3,440.66 million in 2021. This growth represents a compound annual growth rate (CAGR) of 9.5% from 2021 to 2028.

As individuals age, they become increasingly susceptible to heart-related ailments due to weakened immune systems and various health complications. The natural aging process contributes to the stiffening of the heart and blood vessels, which can lead to cardiovascular disorders. With advancing age, systolic blood pressure tends to rise, heightening the risk of cardiovascular diseases (CVDs). In particular, individuals aged 75 and older frequently experience high blood pressure, which is a significant risk factor for heart issues. Other prevalent conditions in this age group include coronary artery disease and heart failure. While arrhythmias can affect people of all ages, their occurrence is notably increasing among the elderly population.

According to the Global Ageing 2019 report, the global population aged 65 and older was approximately 703 million in 2019. This demographic is projected to double, reaching 1.5 billion by 2050. The ratio of individuals aged 65 and above is expected to rise from 1 in every 11 people in 2019 to 1 in every 6 by 2025. This older population is particularly vulnerable to cardiovascular diseases, including arrhythmias. The World Health Organization (WHO) estimates that the proportion of individuals aged 60 and over will increase from 12% in 2015 to 22% by 2050. Furthermore, the report titled "Older Americans 2016: Key Indicators of Well-Being" by the Federal Interagency Forum on Aging-Related Statistics indicates that 35.8% of those aged 85 and older suffer from mild to severe cognitive disorders. Additionally, the United Nations' World Population Ageing 2017 report noted that in 2017, there were 962 million individuals aged 60 and above globally, with projections suggesting this number could reach nearly 2.1 billion by 2050.

The elderly demographic often presents with atypical symptoms, multiple comorbidities, and poorer health outcomes. These challenges are primarily attributed to the structural and functional changes in the cardiovascular system that accompany aging. The increasing global geriatric population is driving a rise in cardiovascular diseases, which in turn is boosting the demand for hemostasis analyzers.

In compiling the report on the hemostasis analyzers market, various primary and secondary sources were utilized, including reputable organizations such as the World Health Organization (WHO), the Centers for Disease Control and Prevention (CDC), and the National Health and Wellness.